Fig. 5From: Proposal for a definition of "Oligometastatic disease in pancreatic cancer"The survival analysis of patients with limited disease + CA 19–9 BL < 1000 U/mL revealed a significantly better overall survival of 16.0 months compared to the rest of the collective (6.9 months; 95% CI 5.7–9.8; p = 0.021)Back to article page